Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2020 · 10-Q
Revenue$502.00K$502.00K+219.7% vs Q2 2019 Net Income-$29.88M-$29.88MN/M vs Q2 2019 EPS Diluted-$0.04-$0.04N/M vs Q2 2019 Operating Income-$30,253,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$25,183,000N/M Margins · derivedOperating margin-6026.5%+16586.2 pt vs Q2 2019
Net margin-5952.2%+20217.9 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end